Patents by Inventor James L. Riley

James L. Riley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210022936
    Abstract: A user module for a patient support is provided. The user module is coupled to a patient support barrier, such as a siderail or a footboard.
    Type: Application
    Filed: October 15, 2020
    Publication date: January 28, 2021
    Inventors: David C. Newkirk, Carl William Riley, James L. Walke, Brian T. Wiggins, Jack B. Wilker, Robert Mark Zerhusen
  • Patent number: 10874727
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 29, 2020
    Assignees: The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Publication number: 20200384029
    Abstract: The present invention relates to modified immune cells or precursors thereof, comprising dual (a first and a second) chimeric receptors (e.g. CARs). One aspect includes a first CAR comprising a 4-1BB intracellular domain and a second CAR comprising a CD28 intracellular domain. Another aspect includes a method for treating of an HIV infected mammal using a modified T cell comprising a first CD4 CAR comprising a 4-1BB intracellular domain and a second CD4 CAR comprising a CD28 intracellular domain.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 10, 2020
    Inventors: James L. Riley, Colby Maldini
  • Patent number: 10842695
    Abstract: A user module for a patient support is provided. The user module is coupled to a patient support barrier, such as a siderail or a footboard.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 24, 2020
    Assignee: Hill-Rom Services, Inc.
    Inventors: David C. Newkirk, Carl William Riley, James L. Walke, Brian T. Wiggins, Jack B. Wilker, Robert Mark Zerhusen
  • Publication number: 20200362012
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 19, 2020
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • Patent number: 10808225
    Abstract: The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: October 20, 2020
    Assignees: The Trustees of the University of Pennsylvania, Government of The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: James L. Riley, Daniel H. Fowler, Shoba Amarnath
  • Publication number: 20200263131
    Abstract: The present invention provides compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells. Accordingly, the invention provides uses of the expanded nTregs for cellular therapy.
    Type: Application
    Filed: March 27, 2019
    Publication date: August 20, 2020
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Patent number: 10738099
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: August 11, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • Patent number: 10669146
    Abstract: A container can be configured for use with an attachment for mixing and dispensing a solution. The container can include an outlet opening for flow out of the container, and a container valve that is configured to control the flow out of the outlet opening. A neck of the container can be oblong, can include a first attachment flange and a second attachment flange, or can include a first attachment shelf and a second attachment shelf.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: June 2, 2020
    Assignee: S.C. Johnson & Son, Inc.
    Inventors: Julie L. Bates, Thomas A. Helf, James R. Crapser, Richard A. Batton, Jeffrey L. Crull, Cunjiang Cheng, Elizabeth Alstad, Casey Frett, Katlyn Garcia, Evan A. Sparks, Joel Kramka, Shawn Smith, Joshua James Riley, James Michael Schlueter
  • Patent number: 10628058
    Abstract: Embodiments of the invention are directed to systems, methods, and computer program products for verifying, storing, and transferring data within an entity. The system is configured for receiving data from one or more source systems, generating a metadata, exposure, and control statement for the data, transferring the data and the metadata, exposure, and control statement to a system of origination, logically classifying the data in the system of record into one or more domains, transferring the data into one or more authorized data sources associated with the one or more domains, receiving a request from a user associated with a target system to retrieve a set of data from the one or more authorized data sources, and transferring the set of data from the one or more authorized data sources to the target system.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: April 21, 2020
    Assignee: BANK OF AMERICA CORPORATION
    Inventors: Mary Kathleen Riley, Renee Marie Melin, Todd David Abbott, Timothy Lamonte Atwell, Edward W. Carroll, Paresh Bhagwandas Chande, Michele Barker Fasciana, Douglas David Foley, Bryan L. Ford, Christopher Ryan Galloway, James Grae Garrison, Brian P. Gibbons, Kecia Marie Heidebrecht, Gayle Tawanda Jackson, Jeffrey Morse Larmondra, Kimberly Lynn Lewis, Srinivasa D. Madireddi, Gautam Suryakant Nipanikar, Michael Harold Perry, Laurie Readhead, Prakash Srinivasan, Kyle S. Sorensen, Constance Jones Suarez, Jeffrey Roger Walls
  • Publication number: 20190367874
    Abstract: This invention relates, inter alia, to compositions of low serum or serum free media and methods for the expansion of T cell populations and methods for using such populations of cells. In some aspects, the invention relates to compositions and methods for the selective expansion of T cell subpopulations.
    Type: Application
    Filed: February 26, 2018
    Publication date: December 5, 2019
    Inventors: Angel M. Varela-Rohena, Melanie B. Andolina, James L. Riley, Andrew Medvec
  • Publication number: 20190177692
    Abstract: Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.
    Type: Application
    Filed: July 26, 2018
    Publication date: June 13, 2019
    Inventors: Carl H. June, James L. Riley, Marcela Maus, Anna Kaskel, Robert Vonderheide
  • Patent number: 10286066
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf’ APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 14, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Davis
  • Publication number: 20190022199
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: June 20, 2018
    Publication date: January 24, 2019
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Publication number: 20180371414
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: May 22, 2018
    Publication date: December 27, 2018
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Publication number: 20180282416
    Abstract: The present invention includes compositions and methods for an HLA-A2 specific chimeric antigen receptor (CAR). In certain embodiments the HLA-A2 specific CAR is expressed on a T regulatory cell. In certain embodiments, the HLA-A2 specific CAR protects transplanted tissue from rejection.
    Type: Application
    Filed: March 27, 2018
    Publication date: October 4, 2018
    Inventors: James L. Riley, Gavin Ellis
  • Publication number: 20180265565
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 20, 2018
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • Patent number: 9994818
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 12, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Publication number: 20170319684
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf’ APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Application
    Filed: December 21, 2016
    Publication date: November 9, 2017
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Davis
  • Publication number: 20170211042
    Abstract: The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.
    Type: Application
    Filed: March 31, 2017
    Publication date: July 27, 2017
    Inventors: James L. Riley, Daniel H. Fowler, Shoba Amarnath